The Thorough Phase I ECG
October 02, 2004
The rapid emergence and global acceptance of new regulatory guidance has thrust cardiac safety to the forefront of new drug development during recent years. This is because the cardiac safety effects of new drugs is the most common cause of drug withdrawal from the market, or delays and a lack of regulatory approval for marketing. The resulting ECG Global Regulatory Imperative creates issues and offers opportunities for new drug developers striving for Best Practices in this important area.